A growing number of biotechnology companies are looking at the Asia-Pacific region to run their clinical trials in oncology. While Australia and New Zealand are preferred locations to run early phase trials, sponsors often look at Asia for large late phase clinical studies. Moreover, clinical trials are often the only channel through which patients can get access to new oncology treatments in Asia which ultimately stimulates patient recruitment rates. During this brief we will discuss:
Dr. Collins has served as Executive Vice President at Five Prime since August 2019 and Chief Medical Officer since March 2017. Prior to joining Five Prime, Helen held multiple positions at Gilead and Amgen and practiced as a medical oncologist and haematologist for 12 years at Redwood Regional Medical Group (RRMG).
Professor Lee specializes in patient derived tumor cells, drug screening, target identification, translational oncology, gastric cancer, colorectal cancer, sarcoma, melanoma, and rare cancers. She co-authored over 200 scientific papers and has participated to over 100 clinical trials.
Ben Tran is a consultant medical oncologist in Melbourne, Australia with appointments at Peter MacCallum Cancer Centre and Walter and Eliza Hall Institute of Medical Research. He is actively involved in clinical trials and translational research, with special interests in genitourinary cancers, drug development and personalized medicine.
Dr Amy Prawira is a medical oncologist specialising in early drug development and head and neck malignancies. She joined the Kinghorn Cancer Centre to lead the Precision Medicine Unit after completing a clinical fellowship under Prof Lillian Siu at the Princess Margaret Cancer Centre in Canada, where she served as a chief fellow for the drug development program. She has been an investigator in over 60 early phase clinical trials, and has been involved in the design and set up of a number of investigator-initiated clinical trials.